Keymed Biosciences Inc. (02162.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 75.00

From 52W high−17.37%

Volume2.55M

Market capHKD 21.52B

P/E (TTM)22.2x

P/S (TTM)22.4x

Div yield—

Key dataSep 18, 2026

Open

HKD 75.00

From 52W high

−17.37%

Volume

2.55M

Market cap

HKD 21.52B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−30.3x

P/E (TTM)

22.2x

RSI (14)

38.3

MomentumView details →

1D Return

−1.23%

YTD Return

+34.80%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

22.2x

EV/EBITDA

−30.3x

EV/Sales

19.3x

P/S (TTM)

22.4x

P/B (TTM)

4.6x

ProfitabilityView details →

Gross Margin

68.24%

Net Margin

92.92%

EBITDA Margin

−63.64%

ROE (TTM)

19.08%

ROA (TTM)

13.48%

Asset Turnover

0.17x

GrowthView details →

Revenue YoY

−5.70%

EPS YoY

+383.67%

FCF YoY

+35.30%

Revenue CAGR 3Y

+91.05%

EPS CAGR 3Y

+5.58%

EBITDA YoY

−67.43%

MomentumView details →

1D Return

−1.23%

YTD Return

+34.80%

1Y Return

−0.07%

RSI (14)

38.3

vs 50D SMA

−8.57%

vs 200D SMA

+9.53%

Capital & dividendView details →

Debt/Equity

0.17x

Current Ratio

4.83x

Quick Ratio

4.55x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

HKD 4.95

EPS Surprise

−6.78%

Beats (12Q)

0/12

Next Q EPS Est

—

Avg Surprise (4Q)

−6.78%

Rev Surprise

0.20%

Financials snapshotView financials →

Revenue (TTM)

1.69B

Net Income (TTM)

506.91M

Op. CF (TTM)

−973.60M

Next earningsMar 30, 2027 →

Latest newsMore news →

Kangnuo-B signed an exclusive licensing agreement with Aeira Pte. Ltd. for the registration and commercialization of its self-developed Stapokibart injection (Kangyueda) in 18 countries and regions in Southeast Asia and Central Asia.18d ago

KeyBanc Capital Markets raised its price target on Keysight Technologies to $210 from $195 and maintained an Overweight rating, citing strong demand for AI-related testing solutions.20d ago

Similar companies

Genmab A/SGMAB United Therapeutics CorporationUTHR Metis Techbio-p07666.HK Zai Lab Limited09688.HK 大参林603233.SH 天坛生物600161.SH Find similar companies →

Latest newsMore news →

Kangnuo-B signed an exclusive licensing agreement with Aeira Pte. Ltd. for the registration and commercialization of its self-developed Stapokibart injection (Kangyueda) in 18 countries and regions in Southeast Asia and Central Asia.18d ago KeyBanc Capital Markets raised its price target on Keysight Technologies to $210 from $195 and maintained an Overweight rating, citing strong demand for AI-related testing solutions.20d ago